E CryoLife Can Return 30% Over The Next Year

CryoLife ( CRY)is a $385M medical device company that also has preservation services. It designs, manufactures and sells surgical sealants, hemostats and specialized implants for cardiovascular repair.Shares trade 41.4X Earnings, 2.48X Sales, and 1.92X Book with a 1% dividend yield and cash-rich balance sheet.

In Q1 CRY posted 27% Y/Y revenue growth, driven by the On-X acquisition. On-X is the best in class mechanical heart valve technology.CRY is undergoing a revamped product portfolio that is targeting accelerated growth in both revenues and margins the next few years. At 2.2X Sales, shares trade cheap to the mean of 3.7X for its peer group. CRY has also reorganized its entire sales rep force to improve results. CRY will be enrolling patients in PerClot IDE trial in the second half and also looking for China FDA approval of BioGlue, two potential positive catalysts for shares.